Trial Profile
Treatment of Steroid-refractory Acute and Chronic Graft-versus-host Disease With Inhibitor of Janus Kinases
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 25 Feb 2020
Price :
$35
*
At a glance
- Drugs Ruxolitinib (Primary)
- Indications Graft-versus-host disease
- Focus Therapeutic Use
- 18 Feb 2020 Results published in the Bone Marrow Transplantation
- 03 Apr 2019 Status changed from recruiting to completed.
- 23 Dec 2016 New trial record